N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Watch our new video animation below to see Nuvec® in action:
Latest news and updates
News: N4 Pharma announces collaboration with SRI to target and treat cells in the human body that have been previously unreachable
Our latest news release for the trade media announces N4 Pharma’s research collaboration agreement with SRI, an independent non-for-profit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary FOX Three Molecular [...]
Interview: N4 Pharma’s CEO Nigel Theobald discusses strategic moves and future of pharma
In an interview with World Pharma Today, Nigel Theobald, CEO N4 Pharma, answers questions about the company’s latest news and future plans. Key highlights from the discussion include: Acquisition: our recent acquisition of Nanogenics Limited [...]
N4 Pharma’s novel delivery systems, Nuvec® and LipTide®, advance towards commercialisation
Our latest news release for trade media highlights our pre-clinical siRNA delivery systems Nuvec® and LipTide®. LipTide® is a lipid and peptide-based delivery system developed by Nanogenics and is currently being used in the formulation [...]